JP2023529354A5 - - Google Patents
Info
- Publication number
- JP2023529354A5 JP2023529354A5 JP2022574452A JP2022574452A JP2023529354A5 JP 2023529354 A5 JP2023529354 A5 JP 2023529354A5 JP 2022574452 A JP2022574452 A JP 2022574452A JP 2022574452 A JP2022574452 A JP 2022574452A JP 2023529354 A5 JP2023529354 A5 JP 2023529354A5
- Authority
- JP
- Japan
- Prior art keywords
- group
- composition according
- ceremony
- carbonyl group
- during
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| IN202041023434 | 2020-06-04 | ||
| IN202041023434 | 2020-06-04 | ||
| PCT/IB2021/054591 WO2021245499A1 (en) | 2020-06-04 | 2021-05-26 | Novel small molecules for targeted degradation of untargetable kras in cancer therapy |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2023529354A JP2023529354A (ja) | 2023-07-10 |
| JP2023529354A5 true JP2023529354A5 (https=) | 2024-06-03 |
| JP7789016B2 JP7789016B2 (ja) | 2025-12-19 |
Family
ID=78830675
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2022574452A Active JP7789016B2 (ja) | 2020-06-04 | 2021-05-26 | 癌治療における標的化不能ｋｒａの標的分解のための新規の小分子 |
Country Status (11)
| Country | Link |
|---|---|
| US (1) | US20230202981A1 (https=) |
| EP (1) | EP4161511B1 (https=) |
| JP (1) | JP7789016B2 (https=) |
| KR (1) | KR20230019937A (https=) |
| CN (2) | CN115768427B (https=) |
| AU (1) | AU2021284517A1 (https=) |
| BR (1) | BR112022024300A2 (https=) |
| CA (1) | CA3180686A1 (https=) |
| IL (1) | IL298672A (https=) |
| MX (1) | MX2022015253A (https=) |
| WO (1) | WO2021245499A1 (https=) |
Families Citing this family (18)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2019217307A1 (en) | 2018-05-07 | 2019-11-14 | Mirati Therapeutics, Inc. | Kras g12c inhibitors |
| EA202190749A1 (ru) | 2018-09-10 | 2021-07-09 | Мирати Терапьютикс, Инк. | Способы комбинированной терапии |
| EP3849535A4 (en) | 2018-09-10 | 2022-06-29 | Mirati Therapeutics, Inc. | Combination therapies |
| JP2022500385A (ja) | 2018-09-10 | 2022-01-04 | ミラティ セラピューティクス， インコーポレイテッド | 組み合わせ療法 |
| EP3849537B1 (en) | 2018-09-10 | 2024-10-23 | Mirati Therapeutics, Inc. | Combination therapies |
| MX2021002804A (es) | 2018-12-05 | 2021-07-15 | Mirati Therapeutics Inc | Terapias de combinacion. |
| EP3908283A4 (en) | 2019-01-10 | 2022-10-12 | Mirati Therapeutics, Inc. | KRAS G12C INHIBITORS |
| MX2022002465A (es) | 2019-08-29 | 2022-05-19 | Mirati Therapeutics Inc | Inhibidores de kras g12d. |
| WO2021061749A1 (en) | 2019-09-24 | 2021-04-01 | Mirati Therapeutics, Inc. | Combination therapies |
| PH12022551513A1 (en) | 2019-12-20 | 2023-04-24 | Mirati Therapeutics Inc | Sos1 inhibitors |
| EP4210833A4 (en) | 2020-09-11 | 2024-09-11 | Mirati Therapeutics, Inc. | CRYSTALLINE FORMS OF A KRAS G12C INHIBITOR |
| JP2023553492A (ja) | 2020-12-15 | 2023-12-21 | ミラティ セラピューティクス， インコーポレイテッド | アザキナゾリン汎ＫＲａｓ阻害剤 |
| EP4262803A4 (en) | 2020-12-16 | 2025-03-12 | Mirati Therapeutics, Inc. | Tetrahydropyridopyrimidine pan-kras inhibitors |
| WO2025083563A1 (en) * | 2023-10-18 | 2025-04-24 | Pillai Universal Llc | Effective therapeutic small-molecule inhibitors for metastatic cancer |
| WO2025083561A1 (en) * | 2023-10-18 | 2025-04-24 | Pillai Universal Llc | Novel lead small molecule inhibitors on undruggable target towards anticancer activity |
| WO2025083564A1 (en) * | 2023-10-18 | 2025-04-24 | Pillai Universal Llc | Novel small molecule degrader as a potential anticancer |
| WO2025083568A1 (en) * | 2023-10-18 | 2025-04-24 | Pillai Universal Llc | Novel small-molecule protein kinase inhibitors for implications in cancer treatment |
| WO2025083570A1 (en) * | 2023-10-18 | 2025-04-24 | Pillai Universal Llc | Novel small-molecule agents in overcoming tumor regression in cancers |
Family Cites Families (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| OA12274A (en) * | 2000-05-22 | 2006-05-09 | Aventis Pharma Inc | Arylmethylamine derivatives for use as tryptase inhibitors. |
| GB0012362D0 (en) * | 2000-05-22 | 2000-07-12 | Aventis Pharma Ltd | Chemical compounds |
| HUP0402106A3 (en) * | 2001-11-01 | 2009-07-28 | Janssen Pharmaceutica Nv | Heteroaryl amines as glycogen synthase kinase 3 beta inhibitors, process for their preparation and pharmaceutical compositions containing them |
| WO2007075896A2 (en) * | 2005-12-22 | 2007-07-05 | Kemia, Inc. | Heterocyclic cytokine inhibitors |
| JP2013525308A (ja) * | 2010-04-16 | 2013-06-20 | キュリス，インコーポレイテッド | Ｋ−ｒａｓ変異を有する癌の治療 |
| US20190284149A1 (en) * | 2014-09-12 | 2019-09-19 | Ariagen, Inc. | Aryl hydrocarbon receptor modulator |
| CN106317055A (zh) * | 2015-07-02 | 2017-01-11 | 中国科学院上海药物研究所 | 一类具有激酶抑制活性的化合物、制备方法和用途 |
| WO2018140513A1 (en) * | 2017-01-26 | 2018-08-02 | Araxes Pharma Llc | 1-(3-(6-(3-hydroxynaphthalen-1-yl)benzofuran-2-yl)azetidin-1yl)prop-2-en-1-one derivatives and similar compounds as kras g12c modulators for treating cancer |
| CN110885332B (zh) * | 2019-12-06 | 2022-03-18 | 中国人民解放军第二军医大学 | 一种PDEδ蛋白降解靶向嵌合体及其制备方法和应用 |
-
2021
- 2021-05-26 US US18/008,332 patent/US20230202981A1/en active Pending
- 2021-05-26 BR BR112022024300A patent/BR112022024300A2/pt unknown
- 2021-05-26 CA CA3180686A patent/CA3180686A1/en active Pending
- 2021-05-26 IL IL298672A patent/IL298672A/en unknown
- 2021-05-26 MX MX2022015253A patent/MX2022015253A/es unknown
- 2021-05-26 KR KR1020237000112A patent/KR20230019937A/ko active Pending
- 2021-05-26 CN CN202180049321.9A patent/CN115768427B/zh active Active
- 2021-05-26 CN CN202510275737.2A patent/CN120208921A/zh active Pending
- 2021-05-26 JP JP2022574452A patent/JP7789016B2/ja active Active
- 2021-05-26 WO PCT/IB2021/054591 patent/WO2021245499A1/en not_active Ceased
- 2021-05-26 AU AU2021284517A patent/AU2021284517A1/en active Pending
- 2021-05-26 EP EP21817859.8A patent/EP4161511B1/en active Active
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2023529354A5 (https=) | ||
| JP2022510313A5 (https=) | ||
| JP2024514837A5 (https=) | ||
| JP2022520061A5 (https=) | ||
| JP2011509309A5 (https=) | ||
| JP2024050527A5 (https=) | ||
| MX2022015253A (es) | Moleculas peque?as novedosas para la degradacion dirigida de kras no dirigibles en la terapia contra el cancer. | |
| JP2011515482A5 (https=) | ||
| JP2019094345A5 (https=) | ||
| CN113365998A (zh) | 用于parp抑制剂的吲哚并七元酰肟类似物 | |
| JP2020517707A5 (https=) | ||
| JP2017502994A5 (https=) | ||
| CA2537127A1 (en) | Benzimidazolone compounds having 5-ht4 receptor agonistic activity | |
| JP2007527919A5 (https=) | ||
| RU2011146059A (ru) | Конденсированное пирролопиридиновое производное | |
| JP2014506907A5 (https=) | ||
| JP2010511721A5 (https=) | ||
| JP2009504764A5 (https=) | ||
| JP2013542267A5 (https=) | ||
| JP2015524443A5 (https=) | ||
| JP2021535159A5 (https=) | ||
| JP2021530487A5 (https=) | ||
| JP2023525359A5 (https=) | ||
| JP2011517697A5 (https=) | ||
| RU2008107733A (ru) | Ингибиторы gsk-3 |